Sip it, FYI nobody is selling or exercising warrants at this SP. The pressure is from the selling of the shares that were purchased to acquire the warrants. Warrants will be exercised only when they are in the money. The majority are at .75 with some at $1.
Your post talking about the importance of BTD Approval is accurate. This is IMO vital to clearing the road for BLA submission and continue are seemingly good graces with the FDA. It would seem the probability of BTD Approval is quite high or Nader would not have applied. The only area of concern I have is I have seen BTD denied for lack of safety data. In this case it would seem that Pro-140 is quite safe - the only issue would be is the quantity of data or patient base adequate to meet FDA safety requirements for BTD Approval. Coming into play is the current status of number of patients that have been enrolled in the P3 Mono. That is where the real support will come from in terms of safety. The way I see it BTD is critical to say the least. If denied it will be a delay in gaining approval-if granted it expedites approval and will be the tipping point we have been waiting for.
News 
Market Data 
Discover 
AI
